3 hours Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Buy” from Analysts MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has received an average rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rec…